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Introduction
• MRAs use in ADCHF may improve congestion through diuretic 
effect and prevent neurohormonal activation
• The impact of MRAs in ADCHF patients has not been well-studied
• We aimed to evaluate the clinical effect and safety of 
spironolactone in ADCHF
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Methods
• Prospective, experimental, single-centre, and single-blinded trial
• Patients were non-randomly assigned to standard ADCHF therapy 
or oral spironolactone 50 -100 mg/d plus standard ADCHF therapy
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Methods
• Major Exclusion Criteria: 
 Plasma Creatinine > 1,5 mg/dL
 Serum Potassium > 5,5 mmol/L
 Sepsis
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Results
No diferences on plasma potassium between groups
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Results
Greater NT-proBNP reduction on Spironolactone group
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Results
Greater proportion of patient free of congestion on Spironolactone group
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Conclusion
• Our study supports the safety of high dose spironolactone in ADCHF and 
suggests a positive impact in the resolution of congestion. 
• The important findings of our pilot study need to be confirmed in larger 
trials
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Limitations
1) No randomization or concealed allocation was performed, we cannot 
exclude a selection bias
2) The assistant physicians performed the congestive signs assessment, 
therefore, we cannot exclude an ascertainment bias
3) Our study was underpowered to detect the differences of the expected 
low rate of adverse events between groups
